Showing results (31-40 of 80) with videos related to
Sort By:
Pageof 8
Pharmaceutical Research|May 6, 2015
Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK ModelJie Zhao, Yanguang Cao, William J JuskoPlos Computational Biology|April 21, 2023
A multispecies framework for modeling adaptive immunity and immunotherapy in cancerTimothy Qi, Benjamin G Vincent, Yanguang CaoThe Journal of Pharmacology and Experimental Therapeutics|July 14, 2018
Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic ModelXiaobing Li, William J Jusko, Yanguang CaoFrontiers in Immunology|June 23, 2023
Incorporating lesion-to-lesion heterogeneity into early oncology decision makingRukmini Kumar, Timothy Qi, Yanguang Cao, et al.Pharmaceutical Research|May 8, 2009
Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in ratsYuancheng Chen, Yanguang Cao, Jia Zhou, et al.Molecular Pharmacology|October 31, 2023
Passive Immunotherapies Targeting Amyloid-β in Alzheimer's Disease: A Quantitative Systems Pharmacology PerspectiveMilica Marković, Jelica Milošević, Weirong Wang, et al.Pharmaceutics|March 15, 2019
Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal DrugsHua He, Dongfen Yuan, Yun Wu, et al.Clinical Pharmacology and Therapeutics|March 13, 2026
Quantitative Lesion-Level Modeling Reveals Organ-Dependent Therapeutic ResponseIan Dilley, Jiawei Zhou, Quefeng Li, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 3, 2013
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodiesYanguang Cao, Joseph P Balthasar, William J JuskoCancer Research|November 3, 2019
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective AnalysisJiawei Zhou, Yutong Liu, Yubo Zhang, et al.Pageof 8